Aytu BioPharma Inc. (Aytu) is set to disclose its financial and operational performance for the third quarter of fiscal year 2024, which concluded on March 31, 2024. This announcement will be made after the stock market closes on Wednesday, May 15, 2024. On the same day, a conference call and webcast are scheduled for 4:30 p.m. Eastern Time to discuss the financial outcomes, followed by a Q&A session.
The conference call can be accessed by dialing (888) 506-0062 for participants in the United States or +1 (973) 528-0011 for international callers, using the participant access code 300411. The webcast will be available live and archived on the Investors section of Aytu's website under Events & Presentations. For those who cannot attend the live session, a replay will be accessible until May 29, 2024, by dialing (877) 481-4010 in the U.S. or +1 (919) 882-2331 internationally, with replay access code 50379.
Aytu BioPharma Inc. is a pharmaceutical company dedicated to bringing innovative therapeutics to the market. Its portfolio includes prescription products such as Adzenys XR-ODT® and Cotempla XR-ODT®—both extended-release orally disintegrating tablets designed for attention deficit hyperactivity disorder (ADHD). Adzenys XR-ODT® contains amphetamine, whereas Cotempla XR-ODT® contains methylphenidate. Both have detailed prescribing information, including Boxed Warnings, that should be reviewed before use.
Other products in Aytu's lineup include Karbinal® ER, an extended-release antihistamine suspension aimed at treating various allergic conditions. Additionally, the company offers Poly-Vi-Flor® and Tri-Vi-Flor®, which are fluoride-based prescription vitamin product lines. These vitamins come in different formulations suitable for infants and children suffering from fluoride deficiency.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!